CymitQuimica logo

CAS 937272-79-2

:

Pacritinib

Description:
Pacritinib is a small molecule inhibitor primarily used in the treatment of certain hematological malignancies, particularly myelofibrosis. It selectively targets Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3), which are involved in the signaling pathways that regulate cell proliferation and survival. This selective inhibition helps to mitigate the symptoms associated with myelofibrosis, such as splenomegaly and constitutional symptoms. Pacritinib is characterized by its oral bioavailability and a unique pharmacokinetic profile, allowing it to be administered without the need for dose adjustments in patients with varying degrees of liver impairment. The compound has been studied for its efficacy and safety in clinical trials, demonstrating a favorable response in patients who have previously been treated with other therapies. As with many targeted therapies, potential side effects may include thrombocytopenia, anemia, and gastrointestinal disturbances, necessitating careful monitoring during treatment. Overall, Pacritinib represents a significant advancement in the therapeutic options available for patients with myelofibrosis.
Formula:C28H32N4O3
InChI:InChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+
InChI key:InChIKey=HWXVIOGONBBTBY-ONEGZZNKSA-N
SMILES:O(CCN1CCCC1)C=2C3=CC(N=C4NC(C=5C=C(C=CC5)COC/C=C/COC3)=CC=N4)=CC2
Synonyms:
  • 14,19-Dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene, 11-[2-(1-pyrrolidinyl)ethoxy]-, (16E)-
  • (16E)-11-[2-(1-Pyrrolidinyl)ethoxy]-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene
  • SB 1518
  • Pacritinib
Found 7 products.